What's Happening?
The field of drug discovery is experiencing a significant transformation with the adoption of New Approach Methodologies (NAMs), including organoids, organs-on-chip, and engineered 3D tissues. These technologies
are moving from proof-of-concept to everyday use in drug screening, discovery, and safety studies. The FDA Modernization Act 2.0 and other regulatory frameworks are accelerating the shift towards non-animal models. This research topic brings together leaders from academia, industry, and regulatory agencies to discuss the current state and future directions of NAMs in drug discovery.
Why It's Important?
The integration of NAMs in drug discovery represents a paradigm shift towards more ethical, efficient, and accurate testing methods. By reducing reliance on animal models, these technologies can improve the predictability of human responses to drugs, potentially leading to safer and more effective treatments. This shift also aligns with regulatory trends favoring non-animal testing methods, which can expedite the drug approval process. As NAMs become more widely adopted, they could revolutionize the pharmaceutical industry, leading to faster and more cost-effective drug development.
